"
Team:SupBiotech-Paris
From 2009.igem.org
(Difference between revisions)
Enguerrand (Talk | contribs) |
Enguerrand (Talk | contribs) |
||
| Line 17: | Line 17: | ||
<br> | <br> | ||
See you guys!<br></font> | See you guys!<br></font> | ||
| + | <br> | ||
| + | <br> | ||
| + | <br> | ||
| + | <br> | ||
| + | <br> | ||
| + | <br> | ||
| + | <br> | ||
| + | <br> | ||
| + | <br> | ||
| + | <br> | ||
| + | <br> | ||
| + | <br> | ||
| + | <br> | ||
| + | <br> | ||
| + | <br> | ||
| + | <br> | ||
| + | <br> | ||
| + | <br> | ||
| + | <br> | ||
| + | <br> | ||
<br> | <br> | ||
<br> | <br> | ||
Revision as of 14:59, 19 August 2009
Project
Introduction Current therapies Gene therapies DVS Concept Tissue Vector Cell Vector Therapeutic plasmid Conclusion Implementation Tissue targeting Antitumor action Treatment modeling Conclusion
Ressources
BioBricks Material & Method Bibliography
Ethics & Safety
Welcome Foreigner,
Our project is a vectorization system, we chose mycobacterium, a microorganism with high tropism for specific tissues, and a synthetic Lambda phage able to infect eukaryotic cells. First, to target tissue, we use mycobacterium, and then to target the cell population, we use the synthetic lambda phage.
See you guys!
